CS
OCUL icon

Credit Suisse’s Ocular Therapeutix OCUL Stock Holding History

Credit Suisse’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3
Closed -$8 – 3579
2022
Q4 		$8 Sell
3
-437
-99% -$1.45K ﹤0.01% 3764
2022
Q3 		$2K Buy
+440
New +$2.22K ﹤0.01% 3747
2022
Q2 		– Sell
-61,043
Closed -$302K – 4188
2022
Q1 		$302K Buy
61,043
+15,841
+35% +$87.8K ﹤0.01% 3225
2021
Q4 		$316K Buy
45,202
+5,692
+14% +$44.2K ﹤0.01% 4102
2021
Q3 		$396K Buy
39,510
+2,233
+6% +$25.1K ﹤0.01% 3957
2021
Q2 		$529K Sell
37,277
-5,520
-13% -$83.9K ﹤0.01% 3806
2021
Q1 		$701K Sell
42,797
-22,158
-34% -$427K ﹤0.01% 3550
2020
Q4 		$1.34M Buy
+64,955
New +$965K ﹤0.01% 3116
2019
Q2 		– Sell
-14,437
Closed -$57K – 4205
2019
Q1 		$57K Buy
+14,437
New +$58K ﹤0.01% 3893
2018
Q3 		– Sell
-33,567
Closed -$226K – 3924
2018
Q2 		$226K Sell
33,567
-1,844
-5% -$12.7K ﹤0.01% 3727
2018
Q1 		$230K Sell
35,411
-889
-2% -$5K ﹤0.01% 3666
2017
Q4 		$161K Sell
36,300
-208,844
-85% -$1.07M ﹤0.01% 3785
2017
Q3 		$1.51M Buy
245,144
+229,349
+1,452% +$1.48M ﹤0.01% 2783
2017
Q2 		$146K Buy
15,795
+2,533
+19% +$24.5K ﹤0.01% 3679
2017
Q1 		$123K Sell
13,262
-39,921
-75% -$332K ﹤0.01% 3678
2016
Q4 		$446K Buy
53,183
+25,569
+93% +$198K ﹤0.01% 3502
2016
Q3 		$189K Buy
27,614
+10,163
+58% +$61.9K ﹤0.01% 3827
2016
Q2 		$86K Buy
+17,451
New +$173K ﹤0.01% 4084
2015
Q3 		– Sell
-31,681
Closed -$667K – 4417
2015
Q2 		$667K Buy
+31,681
New +$785K ﹤0.01% 3508

Other funds holding OCUL

SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Credit Suisse's OCUL Position: Q1 2023 in Review

Credit Suisse sold out of Ocular Therapeutix (OCUL) in Q1 2023, closing a stake of 3 shares — an estimated $8 sold.

Credit Suisse first reported a position in OCUL in Q2 2015 and held it in 19 quarters. The position peaked at $1.51M in Q3 2017. 127 funds tracked by Wall St. Rank hold OCUL as of Q1 2023.

  • Credit Suisse reported no remaining Ocular Therapeutix position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 3 Ocular Therapeutix shares in Q1 2023, an estimated $8.
  • Credit Suisse first reported a position in Ocular Therapeutix in Q2 2015 and held it in 19 quarters.
  • Credit Suisse's Ocular Therapeutix position peaked at $1.51M in Q3 2017.
  • 127 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.